Apogee Therapeutics, Inc. (APGE) — 10-Q Filings
All 10-Q filings from Apogee Therapeutics, Inc.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (5)
-
Apogee's R&D Surge Drives 62% Net Loss Increase to $186M
— Nov 10, 2025 Risk: high
Apogee Therapeutics, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $186.456 million, up from $114.928 -
Apogee's Q2 Net Loss Widens to $55.2M Amid R&D Surge
— Aug 11, 2025 Risk: high
Apogee Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its clinical-stage status. The company's net los -
Apogee Therapeutics Files Q1 2025 10-Q
— May 12, 2025 Risk: medium
Apogee Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position and business activities, including -
Apogee Therapeutics Files Q2 2024 10-Q
— Aug 12, 2024 Risk: medium
Apogee Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business op -
Apogee Therapeutics Files 10-Q for Period Ending March 31, 2024
— May 13, 2024 Risk: low
Apogee Therapeutics, Inc. (APGE) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Apogee Therapeutics, Inc. filed a 10-Q report for the period endi
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX